In last trading session, Merck & Co Inc (NYSE:MRK) saw 13.97 million shares changing hands with its beta currently measuring 0.40. Company’s recent per share price level of $77.62 trading at -$0.65 or -0.83% at ring of the bell on the day assigns it a market valuation of $194.91B. That closing price of MRK’s stock is at a discount of -73.45% from its 52-week high price of $134.63 and is indicating a premium of 5.55% from its 52-week low price of $73.31.

For Merck & Co Inc (MRK), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 1.88. Splitting up the data highlights that, out of 19 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 19 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of 2.06 in the current quarter.

Merck & Co Inc (NYSE:MRK) trade information

Upright in the red during last session for losing -0.83%, in the last five days MRK remained trading in the green while hitting it’s week-highest on Wednesday, 06/04/25 when the stock touched $77.62 price level, adding 1.92% to its value on the day. Merck & Co Inc’s shares saw a change of -21.97% in year-to-date performance and have moved 1.60% in past 5-day. Merck & Co Inc (NYSE:MRK) showed a performance of -1.80% in past 30-days.

Wall Street analysts have assigned a consensus price target of 94 to the stock, which implies a rise of 17.43% to its current value. Analysts have been projecting 82 as a low price target for the stock while placing it at a high target of 106. It follows that stock’s current price would drop -5.64% in reaching the projected high whereas dropping to the targeted low would mean a loss of -5.64% for stock’s current value.

Merck & Co Inc (MRK) estimates and forecasts

This year revenue growth is estimated to rise 1.35% from the last financial year’s standing.

16 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 15.92B for the same. And 15 analysts are in estimates of company making revenue of 17.11B in the next quarter. Company posted 16.11B and 16.66B of sales in current and next quarters respectively a year earlier.

Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 12.04% during past 5 years. In 2025, company’s earnings growth rate is likely to be around 16.39% while estimates for its earnings growth in next 5 years are of 11.66%.

Merck & Co Inc (NYSE:MRK)’s Major holders

VANGUARD GROUP INC is the top institutional holder at MRK for having 244.68 million shares of worth $30.29 billion. And as of 2024-06-30, it was holding 9.6558 of the company’s outstanding shares.

The second largest institutional holder is BLACKROCK INC., which was holding about 207.3 million shares on 2024-06-30. The number of shares represents firm’s hold over 8.1806 of outstanding shares, having a total worth of $25.66 billion.

On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and VANGUARD INDEX FUNDS-Vanguard 500 Index Fund are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025, the former fund manager was holding 79.77 shares of worth $6.19 billion or 3.18% of the total outstanding shares. The later fund manager was in possession of 70.29 shares on Mar 31, 2025, making its stake of worth around $5.46 billion in the company or a holder of 2.80% of company’s stock.